Overview

A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Compare the effect of exenatide (therapeutic and supratherapeutic concentrations), moxifloxacin and placebo on the QT interval.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Eli Lilly and Company
Treatments:
Exenatide
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination